

**ANNOUNCEMENT NO. 270**

2 July 2024

## Preliminary revenue figures for the 2023/24 financial year

In the fourth quarter of the 2023/24 financial year, ChemoMetec's revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period.

The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 400-415 million, disclosed on 8 May 2024.

In the fourth quarter of 2023/24, ChemoMetec sold XcytoMatic instruments for DKK 4.4 million, an increase of 69% compared to the third quarter of the financial year.

**Revenue by product group**

DKKm	Q4 2023/24	Q4 2022/23	Q3 2023/24	2023/24	2022/23
Instruments	32.2	32.0	23.1	117.1	179.0
Consumables	50.4	41.8	52.6	192.5	174.4
Services	25.4	21.4	22.1	93.5	83.0
Other	1.2	1.0	1.1	4.3	5.9
<b>Total revenue</b>	<b>109.2</b>	<b>96.2</b>	<b>98.9</b>	<b>407.4</b>	<b>442.3</b>

In the annual report for 2023/24, which will be published on 11 September 2024, the development in revenue will be further described.

The previously announced guidance for EBITDA in 2023/24 (DKK 185-200 million) is maintained.

**For further information**

CEO Martin Helbo Behrens

Phone: (+45) 4813 1020

## **About ChemoMetec A/S**

*ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies.*

*ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to [www.chemometec.com](http://www.chemometec.com)*